Phio Pharmaceuticals Corp
Research Phio Pharmaceuticals Corp (PHIO) on Bullrun: market cap USD 11.44M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerPHIO
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 11.44M
- Financial periodFY2025
- Net income-USD 8.70M
- Free cash flow-USD 7.99M
Valuation Snapshot
latest market cap is USD 11.44M.
About Phio Pharmaceuticals Corp
Phio Pharmaceuticals Corp., a clinical stage biopharmaceutical company, engages in the development of immuno-oncology therapeutics in the United States. It develops PH-762, an INTASYL compound designed to reduce the expression of PD-1 in multi-center Phase 1b dose-escalating clinical trials; PH-894, an INTASYL compound that is designed to specifically silence BRD4, a protein that controls gene expression in both T cells and tumor cells in preclinical studies.
Frequently asked questions
What is Phio Pharmaceuticals Corp's market cap?
Phio Pharmaceuticals Corp's market capitalization is USD 11.44M.
What does Phio Pharmaceuticals Corp do?
Phio Pharmaceuticals Corp., a clinical stage biopharmaceutical company, engages in the development of immuno-oncology therapeutics in the United States. It develops PH-762, an INTASYL compound designed to reduce the expression of PD-1 in multi-center Phase 1b dose-escalating clinical trials;